Skip to main content
Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc. — Investor Relations & Filings

Ticker · OTLK ISIN · US69012T3059 LEI · 5493007AWUJ6HPMCBH11 US Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2025-03-26 Regulatory Filings
Country US United States of America
Listing US OTLK

About Outlook Therapeutics, Inc.

https://outlooktherapeutics.com/

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of therapies for ophthalmic indications. The company's lead product candidate is ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of retinal diseases, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). If approved in the United States, it would be the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications. The therapy, under the brand name LYTENAVA™ (bevacizumab gamma), has received Marketing Authorization from the European Commission and the UK's MHRA for the treatment of wet AMD. The monoclonal antibody works by inhibiting vascular endothelial growth factor (VEGF).

Recent filings

Filing Released Lang Actions
Regulatory Filings 2025
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-3. It is a formal communication related to a securities registration process, specifically under Rule 461 of the Securities Act of 1933. The document does not contain financial statements, management discussion, or detailed report content. It is a regulatory communication about a filing becoming effective, not the filing itself or a financial report. The document length is short (1982 characters), and it is a letter requesting action rather than a report or announcement of results. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-03-26 English
Regulatory Filings 2025
Regulatory Filings
2025-03-26 English
FORM S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used for registering securities for sale to the public. It includes a prospectus for the resale of common stock by selling stockholders. The document is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to securities registration and offering. This fits the category of Capital/Financing Update (CAP), as it provides updates on the company's fundraising and capital structure changes through the registration of shares for resale.
2025-03-20 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 11, 2025. It includes disclosures about the termination of a material definitive agreement, amendments to articles of incorporation (increase in authorized shares), and submission of matters to a vote of security holders with detailed voting results. The document also references the proxy statement filed earlier and includes voting results from the Annual Meeting. The content primarily consists of announcements about corporate actions and voting results rather than full financial statements or detailed financial analysis. The presence of voting results and descriptions of shareholder proposals aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document is not an Annual Report, Interim Report, or Earnings Release, nor is it a proxy solicitation or management discussion. It is a regulatory filing but more specifically fits the DVA category due to the detailed voting results disclosure. The document length (7836 characters) and content support this classification with high confidence.
2025-03-14 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-03-12 English
Director's Dealing 2025
Director's Dealing
2025-03-12 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.